Non-MNV group (n=153) | Subsequent MNV group (n=23) | P value | |
Follow-up period (months) | 30.0±16.2 | 32.8±17.5 | 0.602* |
Treatment regimens | 0.163 | ||
PDT, n (%) | 89 (58.2) | 15 (65.2) | |
PDT alone, n (%) | 77 (50.3) | 10 (43.5) | |
PDT+anti-VEGF, n (%) | 2 (1.3) | 1 (4.3) | |
PDT+focal laser, n (%) | 10 (6.5) | 4 (17.4) | |
Focal laser, n (%) | 38 (24.8) | 2 (8.7) | |
Anti-VEGF, n (%) | 2 (1.3) | 1 (4.3) | |
Total recurrence, n (%) | 59 (38.6) | 14 (60.9) | 0.043† |
Within the first year, n (%) | 30 (19.6) | 9 (39.1) | 0.104†‡ |
After the first year, n (%) | 29 (19.0) | 5 (21.7) | 1.000†‡ |
Final BCVA, logMAR (Snellen) | 0.02±0.27 (20/21) | 0.15±0.22 (20/28) | <0.001* |
Incomplete resolution on final OCT, n (%) | 48 (31.4) | 17 (73.9) | <0.001† |
SRF, n (%) | 19 (12.4) | 8 (34.8) | 0.002‡ |
PED, n (%) | 23 (15.0) | 3 (13.0) | 1.000‡ |
SRF+PED, n (%) | 1 (0.7) | 6 (26.1) | <0.001‡ |
Macular oedema, n (%) | 5 (3.3) | 0 | 1.000‡ |
Values are the mean±SD or n (%).
*Statistical analysis with the Mann-Whitney U test.
†Statistical analysis with Fisher’s exact test or Pearson’s χ2 test.
‡Bonferroni-adjusted p values.
anti-VEGF, anti-vascular endothelial growth factor; BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; MNV, macular neovascularisation; OCT, optical coherence tomography; PDT, photodynamic therapy; PED, pigment epithelial detachment; SRF, subretinal fluid.